Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Front Immunol. 2021 Feb 24;12:614183. doi: 10.3389/fimmu.2021.614183. eCollection 2021.
Chronic graft-versus-host disease (cGVHD) is one of the most common reasons of late non-relapse morbidity and mortality of patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). While acute GVHD is considered driven by a pathogenic T cell dominant mechanism, the pathogenesis of cGVHD is much complicated and involves participation of a variety of immune cells other than pathogenic T cells. Existing studies have revealed that antigen presenting cells (APCs) play crucial roles in the pathophysiology of cGVHD. APCs could not only present auto- and alloantigens to prime and activate pathogenic T cells, but also directly mediate the pathogenesis of cGVHD multiple mechanisms including infiltration into tissues/organs, production of inflammatory cytokines as well as auto- and alloantibodies. The studies of this field have led to several therapies targeting different APCs with promising results. This review will focus on the important roles of APCs and their contributions in the pathophysiology of cGVHD after allo-HSCT.
慢性移植物抗宿主病（cGVHD）是异基因造血干细胞移植（allo-HSCT）后晚期非复发发病率和死亡率的最常见原因之一。虽然急性移植物抗宿主病被认为是由致病性 T 细胞主导的机制驱动的，但 cGVHD 的发病机制要复杂得多，涉及除致病性 T 细胞以外的多种免疫细胞的参与。现有研究表明，抗原提呈细胞（APCs）在 cGVHD 的病理生理学中发挥着关键作用。APCs 不仅可以提呈自身和同种异体抗原来激活致病性 T 细胞，还可以通过多种机制直接介导 cGVHD 的发病，包括浸润到组织/器官、产生炎症细胞因子以及自身和同种异体抗体。该领域的研究已经产生了几种针对不同 APC 的靶向治疗方法，取得了有前景的结果。这篇综述将重点介绍 APCs 在 allo-HSCT 后 cGVHD 的病理生理学中的重要作用及其贡献。
